SureTrader
Home > Boards > US OTC > Medical - Equipment >

Imagin Medical Inc. (IMEXF)

IMEXF RSS Feed
Add IMEXF Price Alert      Hide Sticky   Hide Intro
Moderator: SO75
Search This Board: 
Last Post: 4/21/2018 7:41:28 PM - Followers: 15 - Board type: Free - Posts Today: 0





 

 

Overview

 Imagin Medical is a medical imaging company
Imagin Medical will establish a new standard of care in the detection and removal of cancer using endoscopes by commercializing an advanced, proprietary and patented imaging technology
 Initially targeting bladder cancer 
 Thereafter expanding to all minimally invasive surgical (MIS) procedures where endoscopes are used
 

Benefits of Minimally Invasive Surgery (MIS)

• Performed using tiny holes or incisions (less muscle cut)
• Reduced pain, smaller / no scarring
• Quicker recovery, shorter hospital stay, less expensive
• Minimally invasive surgeries performed using endoscopes














 


Endoscopic Primer

• Endoscopic means “to look inside”
• Endoscope – a medical device with attached light used to look inside organs
• Endoscopy performed when other tools, such as an MRI, X-ray, or CT scan, are inappropriate
• Endoscopies commonly performed to diagnose cancer, take tissue samples for biopsies, and to remove cancer
• Different medical specialties use different types of endoscopes
• Cystoscopes, Bronchoscopes, Gastroscopes, Laparoscopes
   










 

Endoscopic Market
 
 $46B growing global endoscopy market
 $1B is spent annually in US alone on bladder cancer surveillance
 Bladder cancer is 3rd most common in men and 6th most common in US overall with recurrence rate of 40 – 70% making it the most expensive cancer to treat over the lifetime of a patient
 4 million estimated urology endoscopy procedures performed each year targeting bladder cancer
 Imagin’s disruptive imaging technology squarely addresses limitations in:
• Endoscopies targeting bladder cancer (cystoscopies)
• Endoscopies targeting many other cancers


 


 

Endoscope Limitations - White Light

• Current endoscopes use “white light” (or visible light) that has been the gold standard for decades
• Highly effective for detecting protruding cancerous tumors
• Limitations of white light:
• Tumors that are flat may look the same as normal tissue
• Not effective in visualizing the edges of the tumor
• Inability to illuminate tumors beneath skin surface


 

Endoscope Limitations - Blue Light

• Blue light cystoscopes (white light with blue filter) used with contrasting agents induce fluorescence and improve ability to detect flat cancers and visualize edges
• Drawbacks of existing blue light technology:
• Requires one hour for the agent to be absorbed by bladder
• Surgeon must manually “switch” between white light and blue light to see tumor area
• Repeated usage of imaging agent causes adverse side-effects (FDA limits use of contrast agents to one-time use per patient)
 

 
Disruptive Technology - Endoscopes with i/Blue Imaging System

• Significantly reduced prep time with bladder absorption in less than 15 minutes vs. one hour
• Optics 100,000 X more sensitive
• Simultaneous acquisition of differing images
• No switching back and forth
• Blends the white light and fluorescence images into one
• Enables the surgeon to better visualize and resect the cancer
• This advancement makes i/Blue technology practical, not only for the O.R. but also potentially for the physicians’ office
• Adapts seamlessly to most types of endoscopes on the market
 
Future Development - i/Vision Imaging System

• Incorporates multiple illumination sources in one system
• Accommodates the most commonly used fluorescing contrast agents, i.e., such as those based on the emission of Protoporphyrin IX (PpIX) and Indocyanine green (ICG)
• This instrument enables expansion into multiple endoscopic procedures such as laparoscopic (general and gynecology), colorectal, thoracic and gastroenterology procedures related to cancer and non-cancerous conditions
• Like i/Blue, blends two images into one, adapts to most endoscopes, and orders of magnitude more sensitive
 
Future Development - i/Red Imaging System

• Requires no contrasting agents - uses the fluorescence produced by the body and tumor itself
• Contrast between normal and cancer tissue is potentially related to difference in porphyrin content within the cells
• Dramatically expands the market to endoscopic procedures where imaging agents cannot be practically administered
• Like i/Blue, blends two images into one, adapts to most endoscopes, orders of magnitude more sensitive
 
Intellectual Property

• Underpinning company’s technology are three issued patents and two pending patent applications on technology related to near-infrared spectroscopic imaging for cancer and other medical applications obtained, under exclusive license, from Lawrence Livermore National Security, LLC
• Aim of licensing agreement is to commercialize the technology invented by Dr. Stavros Demos, a key advisor to the company


 
Product Development Roadmap


 
Why Invest in Imagin Medical?

• Key investment risks removed, high investment return potential
• Disruptive cutting edge imaging technology will dramatically reduce bladder cancer recurrence rates addressing $1B growing global market
• Limited R&D risks as concept is proven – this is an execution play
• Experienced medical device management team that has done it before
• Management in medical device field for over 30 years
• Worked together in previous companies
• High-margin product with strong clinical and economic advantages
• Commercial launch expected in 2018 with positive operating cash flows
• Strong acquisition market
• Most medical device companies grow by acquisition, not organically
• Company expected to have significant value with multiple liquidity options
 

 
Number of Shares Outstanding as at August 31, 2017:                50,068,739
 
Shares Subject to Resale Restrictions    
1) Shares subject to escrow (1,725,000 released every 6 months - Feb 9 & Aug 9) 5,175,000  
2) Performance shares 5,000,000  
Total Shares Subject to Resale Restrictions   10,175,000
Total Tradeable Float   39,893,739
Total Shares Outstanding   50,068,739

Number of Warrants Outstanding as at August 31, 2017:             25,005,064
 
Warrants Outstanding    
Feb 2016 Private Placement Strike @ 0.35 - expire Feb 9, 2018 7,007,413
Q4/2016 PP - Tranche 1 Strike @ 0.12 / 0.16 - expire Oct 20, 2018 5,111,300
Q4/2016 PP - Tranche 2 Strike @ 0.12 / 0.16 - expire Dec 9, 2018 3,980,565
Warrants from BSS acquisition Strike @ 0.15 - expire Feb 9, 2019 8,905,786
Total Warrants Outstanding   25,005,064

Number of Options Outstanding as at August 31, 2017:                3,350,000
 
 Management Options Outstanding    
Tranche 1 Strike @ 0.15 3,350,000
Total Options Outstanding   3,350,000
 
Various Company Links

Company Web Site
Corporate Presentation (10/2/2017)

CSE Web Site for Imagin Medical
SEDAR Web Site for Imagin Medical

Listing Statement CSE - February 16, 2016

Share Issuance - February 9, 2016
Share Issuance - August 22, 2016
Share Issuance - October 21, 2016
Share Issuance - December 13, 2016
Convertible Debt Issuance - March 3, 2017
Share Issuance - October 4, 2017

Option Grant - June 30, 2016
Option Grant - December 19, 2016
Option Grant - April 10, 2017

Information Circular - October 31, 2016

Monthly CSE Filings (CSE Form 7)
 
  2016 2017
January N/A Link
February Link Link
March Link Link
April Link Link
May Link Link
June Link Link
July Link Link
August Link Link
September Link  
October Link  
November Link  
December Link  

Financial Statements (FS) & Management Discussion and Analyses (MD&A)
 
      2015 2016 2017
Q2 Quarter Ended March 31 FS   Link Link
MD&A   Link Link
Q3 Quarter Ended June 30 FS   Link Link
MD&A   Link Link
Q4 Quarter Ended September 30 FS Link Link  
MD&A Link Link  
Q1 Quarter Ended December 31 FS Link Link  
MD&A Link Link  

 

 
SureTrader
IMEXF
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
PostSubject
#579  Sticky Note Capital Ideas Episode 25 SO75 03/14/18 01:40:25 PM
#708   Ur torturing your mind wth numbers that cannot AMG 04/21/18 07:41:27 PM
#707   lith, thx. Was hoping they would give a 7Card 04/21/18 05:23:51 PM
#706   https://www.imaginmedicalstock.com/ lithiumjr 04/21/18 03:30:36 PM
#705   The insiders are fully loaded with shares and 7Card 04/21/18 12:27:20 AM
#704   Insider Trade Volume (Q3-17, Q4-17, Q1-18) AMG 04/20/18 10:43:50 PM
#703   I come up with 171 7Card 04/20/18 02:12:37 PM
#702   It's way more than that. Someone was working SO75 04/20/18 01:56:33 PM
#701   Curious it says 122M shs outstanding. 7Card 04/20/18 01:36:11 PM
#700   It was in yesterdays PR. SO75 04/20/18 11:02:28 AM
#699   Form 11 is this new info?? alwaysliquid 04/20/18 10:56:03 AM
#698   Stacking Up AMG 04/20/18 10:08:40 AM
#697   CFO and CEO insider buy yesterday... lithiumjr 04/20/18 09:36:09 AM
#696   +1 All some folks have ever known or think AMG 04/20/18 08:47:50 AM
#695   Are you joking!!! $150 mkt cap is 7Card 04/20/18 02:09:29 AM
#694   $150 US market cap will happen... lithiumjr 04/19/18 09:39:47 PM
#693   Nice day. Should be on our way to SO75 04/19/18 04:05:54 PM
#692   The Next Big Thing In Cancer Detection AMG 04/19/18 02:48:16 PM
#691   Imagin Medical valuation possibilities --Urologists perform about 4 7Card 04/19/18 02:20:24 PM
#690   $IMEXF 100x More Accurate at Visualizing Tumors lithiumjr 04/19/18 01:30:30 PM
#689   Dr Roger Buckley upped his ante in IME. SO75 04/19/18 11:35:57 AM
#688   Well let's drive it home then Jim. Let's hope SO75 04/19/18 09:15:01 AM
#687   Imagin Medical Closes Oversubscribed Private Placement lithiumjr 04/19/18 08:46:20 AM
#686   They are not the best promoters for a SO75 04/17/18 02:15:33 PM
#685   The video is a simple restatement of the 7Card 04/17/18 02:04:11 PM
#684   Agreed. News to say the PP is closing AMG 04/17/18 02:01:54 PM
#683   1 more thing that bothered me was they SO75 04/17/18 01:02:51 PM
#682   I would say no because i already suggested SO75 04/17/18 12:45:07 PM
#681   Excellent critique SO75. You think it's possible you AMG 04/17/18 12:40:31 PM
#680   The presentation was horrible. And rehashed all the SO75 04/17/18 12:35:10 PM
#679   So you do or you don't want them AMG 04/17/18 12:21:34 PM
#678   On a side note we had an insider SO75 04/17/18 12:03:16 PM
#677   Yes it is paid promo. I'm not all SO75 04/17/18 11:39:24 AM
#676   Thanks for the video post. I am IMeasy 04/17/18 11:05:49 AM
#675   $IMEXF video feature lithiumjr 04/17/18 09:13:06 AM
#674   166M share count is what I come up 7Card 04/16/18 12:46:17 AM
#673   And then there is the option that IMEXF IMeasy 04/15/18 12:19:29 AM
#672   SHARE COUNT: I am trying to IMeasy 04/15/18 12:16:17 AM
#671   A billion dollar valuation works for me. 7Card 04/14/18 01:07:02 AM
#670   IMO, everyone invested now has taken the "ahead AMG 04/13/18 10:28:23 PM
#669   Wonder how large a slice of the projected 7Card 04/13/18 12:52:29 PM
#668   +2 TommyTuna 04/12/18 06:59:42 PM
#667   +1 AMG 04/12/18 05:56:04 PM
#666   I added another 100k. IME will be big. 7Card 04/12/18 01:19:34 PM
#665   We may be over reacting to the recent MSU 04/12/18 01:16:36 PM
#664   GREAT READ $IMEXF, hints buyout by Boston Scientific lithiumjr 04/12/18 09:27:49 AM
#663   Apparently Jim CEO wanted these people on board 7Card 04/11/18 04:09:39 PM
#662   Why do you think he diluted the company MSU 04/11/18 10:02:46 AM
#661   I don't give a damn how "prudent" a AMG 04/10/18 08:32:46 PM
#660   IMeasy, excellent thoughts and very well said. 7Card 04/10/18 06:05:01 PM
#659   Some people buy a stock and have no IMeasy 04/10/18 02:08:49 PM
PostSubject